Article

Ultra-deep sequencing reveals no evidence of oncogenic mutations or enrichment by ex vivo CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells

2021-10-27

Abstract excerpt

As CRISPR-based therapies enter the clinic, evaluation of the safety remains a critical and still active area of study. While whole genome sequencing is an unbiased method for identifying somatic mutations introduced by ex vivo culture and genome editing, this methodology is unable to attain sufficient read depth to detect extremely low frequency events that could result in clonal expansion. As a solution, we util...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e27854d6-8c9f-5477-89c4-9c00529ca41d
DOI: 10.1101/2021.10.27.466166

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ultra-deep sequencing reveals no evidence of oncogenic mutations or enrichment by ex vivo CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cellsDOI 10.1101/2021.10.27.466166Read

Genome-Wide Analysis of Off-Target CRISPR/Cas9 Activity in Single-Cell-Derived Human Hematopoietic Stem and Progenitor Cell ClonesSemantic proximity Read

Comparative analysis of CRISPR off-target activity discovery tools following ex vivo editing of CD34 + hematopoietic stem and progenitor cellsSemantic proximity Read

Genome-wide structural variant landscape following HDR-enhanced CRISPR editing in human hematopoietic stem and progenitor cellsSemantic proximity Read

Editing of ADA2 Point Mutation in Human Hematopoietic Stem CellsSemantic proximity Read

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells.Semantic proximity Read

Understanding genetic heterogeneity in gene-edited hematopoietic stem cell products.Semantic proximity Read

Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential HurdlesSemantic proximity Read

Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasmsSemantic proximity Read

Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cellsSemantic proximity Read

Genome editing to model and reverse a prevalent mutation associated with myeloproliferative neoplasmsSemantic proximity Read

Detection of deleterious on-target effects after HDR-mediated CRISPR editingSemantic proximity Read

Human genetic diversity alters therapeutic gene editing off-target outcomesSemantic proximity Read

Ultra-deep sequencing reveals no evidence of oncogenic mutations or enrichment by <i>ex vivo</i> CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells

Abstract excerpt

Topics

Identifiers and source

Related research